Antibody-Dependent Effector Functions Against HIV Decline in Subjects Receiving Antiretroviral Therapy

• Published in: The Journal of infectious diseases Vol. 211; no. 4; pp. 529 - 538
• Main Authors: Madhavi, Vijaya, Ana-Sosa-Batiz, Fernanda E., Jegaskanda, Sinthujan, Center, Rob J., Winnall, Wendy R., Parsons, Matthew S., Ananworanich, Jintanat, Cooper, David A., Kelleher, Anthony D., Hsu, Denise, Pett, Sarah, Stratov, Ivan, Kramski, Marit, Kent, Stephen J.
• Format: Journal Article
• Language: English
• Published: United States Oxford University Press 15.02.2015
• Subjects: Anti-Retroviral Agents - administration & dosage; Anti-Retroviral Agents - adverse effects; Anti-Retroviral Agents - therapeutic use; Antibody-Dependent Cell Cytotoxicity - drug effects; Antibody-Dependent Cell Cytotoxicity - immunology; Cohort Studies; env Gene Products, Human Immunodeficiency Virus - immunology; HIV Infections - drug therapy; HIV Infections - epidemiology; HIV Infections - immunology; HIV-1 - immunology; HIV/AIDS; Human immunodeficiency virus; Humans; Immunoglobulin G - blood; Immunoglobulin G - immunology; Killer Cells, Natural - immunology; Longitudinal Studies; Monocytes - immunology; Viral Load; monocytes; NK cells; HIV; ADCC; ADP; cART
• ISSN: 0022-1899; 1537-6613; 1537-6613
• DOI: 10.1093/infdis/jiu486

Background. Combination antiretroviral therapy (cART) effectively controls human immunodeficiency virus (HIV) infection but does not eliminate HIV, and lifelong treatment is therefore required. HIV-specific cytotoxic T lymphocyte (CTL) responses decline following cART initiation. Alterations in other HIV-specific immune responses that may assist in eliminating latent HIV infection, specifically antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent phagocytosis (ADP), are unclear. Methods. A cohort of 49 cART-naive HIV-infected subjects from Thailand (mean baseline CD4 count, 188 cells/μL; mean viral load, 5.4 log₁₀ copies/mL) was followed for 96 weeks after initiating cART. ADCC and ADP assays were performed using serum samples obtained at baseline and after 96 weeks of cART. Results. A 35% reduction in HIV type 1 envelope (Env)-specific ADCC-mediated killing of target cells (P < .001) was observed after 96 weeks of cART. This was corroborated by a significant reduction in the ability of Env-specific ADCC antibodies to activate natural killer cells (P<.001). Significantly reduced ADP was also observed after 96 weeks of cART(P=.018). Conclusions. This longitudinal study showed that cART resulted in significant reductions of HIV-specific effector antibody responses, including ADCC and ADP. Therapeutic vaccines or other immunomodulatory approaches may be required to improve antibody-mediated control of HIV during cART.